|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After 5 years of motor symptoms, 24% of participants met the criteria for MCI and 69% for dementia.
|
31678902 |
2020 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnosis of dementia at follow-up (obtained using clinical diagnostic criteria) constituted the reference standard, and all the included aMCI patients were divided into two groups: the aMCI converters (MCI-C) and MCI nonconverters (MCI-NC).
|
31744965 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whilst the Look-AHEAD study found no impact on diagnosis of MCI or dementia, the LIFE study demonstrated beneficial effects on global cognitive function and delayed memory specifically in older adults with T2DM.
|
30825309 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We included 493 patients and controls from the Gothenburg MCI study and used the dementia groups for marker selection (CSF total-tau (T-tau), phospho-tau (P-tau), and amyloid-β42 (Aβ42), 11 neuropsychological tests, and 92 regional brain volumes) and to obtain cut-off values which were then applied to the MCI groups.
|
31815692 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four studies suggest higher prevalence of MCI and neurodegenerative disease among NFL retirees, although a quantifiable risk and prevalence of cognitive impairment and dementia in these players remains unknown.
|
31592681 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most of the participants who developed dementia were diagnosed at baseline with amnestic multidomain MCI.
|
31455461 |
2020 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MCI diagnosis was based on medical evaluations through a clinical interview conducted by a dementia specialist.
|
31261796 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mild cognitive impairment (MCI) generally evolves in a gradually progressive decline in memory and non-memory cognitive domains that may eventually decay to dementia.
|
30958367 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the amyloid-adjusted logistic regression models, p-tau was a significant predictor for PET-amyloid in SCD (OR = 1.02 [1.01-1.04], p<sub>FDR</sub> = 0.03), MCI (OR = 1.05 [1.02-1.07], p<sub>FDR</sub> < 0.01), and dementia (OR = 1.04 [1.03-1.05], p<sub>FDR</sub> < 0.001), but not for CSF-amyloid.
|
31810489 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Physical inactivity and executive dysfunction were associated with physical decline in this sample, which included participants with MCI and dementia.
|
29798680 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals aged 55-75 years who live in the United States and self-report not having a diagnosis of cognitive impairment such as MCI or dementia are eligible to join GeneMatch.
|
30772251 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further high-quality evidence is needed in order to determine whether mind-body interventions are cost-effective for improving cognitive decline in older adults with MCI and for delaying the rapid progression from MCI to Alzheimer or other types of dementia.
|
30712518 |
2019 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used, firstly, a clinical cohort at a dementia clinic (National Health Insurance Service-Ilsan Hospital [NHIS-IH]; N = 211; 110 AD, 64 mild cognitive impairment [MCI], and 37 cognitively normal with subjective memory complaints [SMC]) to test the diagnostic models; and, secondly, Alzheimer's Disease Neuroimaging Initiative (ADNI)-2 to test the generalizability.
|
31150957 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were 38 controls, 26 patients with pure ADCI (18 mild cognitive impairment [MCI] and 8 dementia), 28 patients with pure LBCI (13 MCI and 15 dementia), and 54 patients with mixed ADCI and LBCI (17 MCI and 37 dementia).
|
30944239 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Depression and SCD demonstrated independent risks of MCI/dementia (HR 1.4 and 2.0 respectively).
|
31399132 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only the short variant by Roalf et al was comparable to the original MoCA in identifying MCI or dementia even across education subgroups.
|
30910550 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a systematic literature review on Subjective Cognitive Decline (SCD) in order to examine whether the resemblance of brain connectome and functional connectivity (FC) alterations in SCD with respect to MCI, AD and HC can help us draw conclusions on the progression of SCD to more advanced stages of dementia.
|
31401485 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Logistic regression models were used to determine odds ratios (OR) and 95% confidence intervals (CI) for the association between HDL-C quartiles and MCI and dementia, respectively.
|
30659169 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additional subgroup analyses (MCI versus dementia, Aβ-positive versus Aβ-negative subjects) were performed.
|
30636731 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that AD8 can show dementia and MCI when the cut-off values are ≥5 and 3-4, respectively, with a sensitivity of 100% and 81.67% and specificity of 96.3% and 93.59%.
|
29923472 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In turn, MCI or dementia were associated with increased disability and aggressive behavior.
|
31301619 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCM demonstrates corneal nerve fiber loss, which is associated with a decline in cognitive function and functional independence in patients with MCI and dementia.
|
31019993 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extending the discriminative validity analysis to cognitive impairment (both dementia and MCI, n = 162) only slightly reduced the discriminative validity of BASIC whereas the discriminative validity of the MMSE was substantially attenuated.
|
31389089 |
2019 |
|
Presenile dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (<sup>18</sup>F-flortaucipir and <sup>18</sup>F-florbetaben), MRI, and neuropsychologic tests.
|
30926651 |
2019 |
|
Presenile dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The proportion of A+T+N+ patients increased with syndrome severity (from 1% in SCD to 14% in MCI and 35% in dementia), while the opposite was true for A-T-N- (from 48% to 19% and 6%).
|
31597710 |
2019 |